On November 3, 2026 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported its participation in the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in Phoenix, Arizona. The Company’s participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our presence at SITC (Free SITC Whitepaper) underscores the promise of our off-the-shelf CAR T platform, from clinical progress in solid tumors to next-generation innovation informed by learnings across our pipeline," said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics. "We are building on this experience to develop a new generation of cell therapies with the potential to expand patient access, reach more treatment settings and transform care across oncology and autoimmune disease."

Scientific Presentation: Advancing a First-in-Class Allogeneic CAR T Approach in Renal Cell Carcinoma: Clinical Experience from the TRAVERSE Study
Thursday, November 5, 2026
9:05-9:15 a.m. MT
Jeffrey McLeroy, M.D.
Session I: Cell Therapies and Technologies
Sheraton, 2nd Level – Valley of the Sun Ballroom

Scientific Presentation: Allogeneic CAR T: A Platform Built for Patient Access – in Cancer and Beyond
Friday, November 6, 2026
4:25-4:40 p.m. MT
Zachary Roberts, M.D., Ph.D.
Biotech Session 107b: Next Generation of Off the Shelf I/O
Phoenix Convention Center, North Building, 300 Level, Halls BC

Complementing these presentations, the Company will present preclinical data evaluating a novel off-the-shelf DLL3/CD70 dual CAR T product candidate for small cell lung cancer and other neuroendocrine tumors. The findings suggest that careful selection of the genomic location for site-specific-integration of the CAR can improve CAR T cell performance in controlling tumors. Confirming and extending observations presented earlier this year with BCMA, the data show pairing the DLL3 CAR with a CAR targeting CD70 can enhance resistance to immune-mediated rejection, illustrating that Dagger technology can be coupled with other CARs. These findings reinforce the potential of the Dagger technology as a versatile foundation for Allogene’s next-generation pipeline, supporting the development of off-the-shelf CAR T therapies across additional targets for both hematological and solid tumors as well as autoimmune disease.

Poster: Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors
Friday, November 6, 2026
Abstract #207
12:15-1:45 p.m. MT and 5:30-7:00 p.m. MT
Presenter: Zhe Li, Ph.D.
Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-5

(Press release, Allogene, NOV 3, 2026, View Source [SID1234674105])